Ertapenem Sodium, EvoPure®

- Overview
  - Ertapenem Sodium, EvoPure® is a highly purified form of Ertapenem Sodium. It is a broad-spectrum carbapenem that interferes with peptidoglycan synthesis.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    β-lactams interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues, providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to β-lactams is commonly due to cells containing plasmid-encoded β-lactamases.
- Properties
  - CAS Number
    
    153773-82-1
    
    Molecular Formula
    
    C22H24N3O7S • Na
    
    Molecular Weight
    
    497.50
    
    Appearance
    
    White or light yellow powder
    
    Solubility
    
    Sparingly soluble in water (20 mg/mL)
    
    Other Properties
    
    Source: Synthetic
    Identification: Confirmed by: IR, NMR, and Mass Spec.
    Purity Level: (HPLC, As Is): ≥98.0%
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Ertapenem Sodium has broad-spectrum activity targeting a wide spectrum of aerobic and anaerobic Gram-positive and Gram-negative bacteria.
    
    Microbiology Applications: Ertapenem Sodium is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options. Representative MIC values include:
    Staphylococcus aureus: 0.12 µg/mL – >16 µg/mL
    Escherichia coli: ≤ 0.008 - 0.5 µg/mL
    It is active against cephalosporin-resistant enteric organisms producing Extended-Spectrum Beta-Lactamases (ESBLs) and penicillin-resistant Streptococcus pneumoniae. It has restricted activity against nosocomial pathogens including Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant staphylococci and enterococci.